timothy sykes logo

Stock News

Iovance Biotherapeutics Plummets Amidst Lawsuit and Executive Shake-up

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Updated 7/25/2025, 11:32 am ET 7/25/2025, 11:32 am ET | 4 min 4 min read
Iovance Biotherapeutics Plummets Amidst Lawsuit and Executive Shake-up Thumbnail

Stocks of Iovance Biotherapeutics Inc. have been trading down by -6.84 percent amid market reactions and investor sentiment.

Candlestick Chart

Live Update At 11:32:07 EST: On Friday, July 25, 2025 Iovance Biotherapeutics Inc. stock [NASDAQ: IOVA] is trending down by -6.84%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Recently, Iovance Biotherapeutics faced a turbulent period marked by financial challenges, signaling potential obstacles ahead. The company’s earnings report depicted a concerning scenario — with a significant negative profitability margin, revenue clocking in at $164.07M, but bearing a steep pretax loss margin of over -870%. Despite positive signs like a sufficient liquidity reflected by a strong current ratio of 4.2, the profitability ratios showed worrying figures. The massive losses reflected in their income statements signaled possible rough waters ahead.

On a typical trading day, fluctuations bring color to market charts, but in this scenario, numbers swung wildly. The IOVA stock opened at $3.415 the other day but closed at a slightly lower $3.065, muddying the waters for potential investors. Taking a closer look, the 5-minute chart bore witness to volatile spikes, portraying a vivid tale of instability, securing the notion of a topsy-turvy trading ambiance.

Market Reactions

The latest set of articles paints a picture of a spiraling situation for Iovance Biotherapeutics. Shares plummeted drastically, with investors scrambling for clarity amidst a slew of securities fraud allegations. Class action suits citing false claims and misleading statements faced by the company opened stormy skies, reflecting adverse impacts on their stock price.

The unexpected resignation of their CFO Jean-Marc Bellemin amidst the underperformance of the company’s flagship drug, Amtagvi, added fuel to the fire. Investors felt the tremors, watching the company’s stock slide downwards. Furthermore, UBS and Goldman Sachs downgrades, cutting the price target substantially, further weighed down investor confidence.

Every twist and turn in this troubling saga undeniably impacted the company’s prospects, challenging its strategic position in the biotech sphere. Revenue forecasts took a significant hit amidst declining investor trust, as faith wavered in the company’s ability to climb out of this predicament.

More Breaking News

Conclusion

Navigating through troubled waters, Iovance Biotherapeutics stands at a crossroads amidst swirling controversies, leadership changes, and financial woes. Traders face a moment of reckoning in deciding their next moves in weathering the turmoil overshadowing potential growth prospects. As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.”

Transparency, trust, and strategic recalibration stand as key pillars needed for a future turnaround. While the seas are rough, as crucial insights emerge, traders must remain vigilant and informed, weighing opportunities against inherent risks, as this biotech player rides the wave of uncertainty.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”